DICE Therapeutics (NASDAQ:DICE) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock. HC Wainwright also issued estimates for DICE Therapeutics’ Q1 2023 earnings at ($0.57) EPS, Q3 2023 earnings at ($0.70) EPS and Q4 2023 earnings at ($0.76) EPS.

A number of other equities analysts have also commented on the stock. Cowen began coverage on shares of DICE Therapeutics in a research report on Wednesday, March 1st. They issued an outperform rating for the company. TD Cowen initiated coverage on shares of DICE Therapeutics in a report on Wednesday, March 1st. They issued an outperform rating on the stock. Finally, Cowen initiated coverage on shares of DICE Therapeutics in a report on Wednesday, March 1st. They set an outperform rating on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, DICE Therapeutics currently has a consensus rating of Buy and a consensus price target of $65.86.

DICE Therapeutics Stock Down 2.3 %

Shares of NASDAQ:DICE opened at $28.82 on Thursday. The firm has a market capitalization of $1.37 billion, a PE ratio of -13.47 and a beta of 0.71. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $45.99. The company has a 50-day moving average price of $29.87 and a two-hundred day moving average price of $29.43.

Institutional Investors Weigh In On DICE Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Voya Investment Management LLC increased its position in shares of DICE Therapeutics by 161.1% during the 4th quarter. Voya Investment Management LLC now owns 29,293 shares of the company’s stock valued at $914,000 after purchasing an additional 18,074 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of DICE Therapeutics by 3.1% during the 4th quarter. Alliancebernstein L.P. now owns 26,900 shares of the company’s stock valued at $839,000 after purchasing an additional 800 shares during the last quarter. Metropolitan Life Insurance Co NY increased its position in shares of DICE Therapeutics by 20.3% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 2,223 shares of the company’s stock valued at $69,000 after purchasing an additional 375 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of DICE Therapeutics by 18.4% during the 4th quarter. MetLife Investment Management LLC now owns 18,851 shares of the company’s stock valued at $588,000 after purchasing an additional 2,930 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of DICE Therapeutics by 205.3% during the 4th quarter. Jane Street Group LLC now owns 16,118 shares of the company’s stock valued at $503,000 after purchasing an additional 31,418 shares during the last quarter. Hedge funds and other institutional investors own 91.51% of the company’s stock.

DICE Therapeutics Company Profile

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.